Large and mid-cap vaccine makers are, as of now, unworried about their 2025 pipelines in the face of research funding ...

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's a portfolio of dividend shares that could produce £115 of monthly passive income for investors who maximise their ISA ...

In a report released today, Jo Walton from UBS maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of ...

The shares have sprung back to life thanks to China’s new stimulus programs—and Alibaba’s AI ventures. They stand to gain as much as 48%.